Aratana Therapeutics (PETX) Posts Q1 Loss of 34c/Share

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $176 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Aratana Therapeutic (PETX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• Innovaro (INV) Misses Q2 EPS by 9c